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Introduction 
Cystathionine ~-synthase (CBS) deficiency was first 
demonstrated in 1964 in an eight-year-old mentally 
retarded girl with bilaterally dislocated optic lenses 
who excreted abnormally elevated amounts of homo-
cystine in her urine {l]. Patients with similar meta-
bolic abnormalities and clinical findings had first 
been discovered 2 years earlier by Carson and her 
colleagues during a survey of mentally backward 
children in Northern Ireland [2}. CBS deficiency 
has proven to be the most frequently encountered of 
the human genetic diseases causing homoeystinuria 
and severe hyperhomocyst(e)inemia. Worldwide, it is 
detected with a frequency of about 1: 344,000 by 
screening programs of the newborn, but this is un-
doubtedly an underestimate because some indi-
viduals are being missed [3]. This chapter will briefly 
focus on the major clinical manifestations and meta-
bolic aspects of CBS deficiency. 
Major Clinical Features 
Clinically, the most prominent features of CBS defi-
ciency are mental retardation, dislocation of the optic 
lenses, a tendency toward early thromboembolic 
events, and osteoporosis and other bony abnormali-
ties. An international survey published in 1985 [4} 
presented data on 629 CBS-deficient patients. Among 
those so classified, some 44% were judged to be B6-
responsive; that is, when given high doses of pyridox-
ine they underwent prompt and marked decreases in 
plasma homocyst(e)ine and methionine concentra-
tions. An equal proportion were judged nonrespon-
sive, with little or no decreases in the abnormally 
elevated concentrations of these amino acids follow-
ing pyridoxine administration. Although this crude 
classification is undoubtedly an oversimplification, 
the results clearly showed that in the absence of spe-
cific treatment, as a group the B6-nonresponsive pa-
tients were more severely affected clinically than were 
the B6-responsive patients. The median IQ for 
nonresponders was 56; for responders, 78. Among 
untreated patients, optic lens dislocation had oc-
curred in 50% of nonresponders by age six years, a 
clinically apparent thromboembolic event had oc-
curred in 25% of patients by age 15 years, and spinal 
osteoporosis was detected in 50% by age 12. By con-
trast, the corresponding ages for untreated B6-
responders were 10,20, and 20 years. 
Metabolic Aspects 
The primary abnormality in CBS-deficient patients is 
a failure to covert homocysteine to cystathionine, a 
process that normally must occur chiefly in the liver. 
Mansoor and colleagues [5} have shown that in nor-
mal plasma, only 2% of the homocysteine-derived 
moieties exist as homocysteine itself; 16% occur as 
free disulfides (homocystine, homocysteine-cysteine 
mixed disulfide, other mixed disulfides); and 82% are 
bound to protein as mixed disulfides of homocysteine 
and protein cysteine [5}. Comparable measurements 
by modern methods have not been reported for in-
tracellular homocysteine-derived moieties in CBS-
deficient patients. Clearly there is some export of 
the abnormally accumulated homocysteine so that the 
total plasma homocyst(e)ine (tHcy) rises dramatically. 
The greatest relative rise occurs in homocysteine, with 
lesser rises in free disulfides and the protein-bound 
mixed disulfide (up to 400-fold, 90-fold, and 20-fold 
above normal, respectively) [6}. Plasma methionine 
also rises in most CBS-deficient patients, presumably 
due to enhanced methylation of abnormally elevated 
homocysteine. The source(s) of the methyl group for 
such methylation is (are) uncertain. The availability 
of betaine must be limiting under normal dietary 
conditions because administration of betaine usually 
results in further decreases in tHey. N 5 -Methyltetra-
hydrofolate would be expected to provide an 
alternative supply of methyls (see below). 
Additional compounds that would be expected to 
accumulate abnormally in cells of CBS-deficient pa-
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tients include S-adenosylhomocysteine (AdoHcy) (if 
adenosine is available) and S-adenosylmethionine 
(AdoMet). The former is expected to accumulate be-
cause the equilibrium of AdoHcy hydrolase favors 
AdoHcy formation, and the latter because of the el-
evated methionine concentration in the presence of 
intact methionine adenosyltransferase that (in the 
liver) is normally operating far below saturation with 
respect to that substrate. Neither of these compounds 
has been measured in liver or other tissue of CBS-
deficient patients by use of methods that are now 
known to be necessary to avoid rapid changes after 
tissue is removed from the body. Indirect evidence 
for an abnormal elevation of AdoHcy is provided 
by the fact that Perry and coworkers {7,8) found 
unusual amounts of this compound and of 5-amino-4-
imidazolecarboxamide-5' -S-homocysteinylriboside, a 
compound structurally (and presumably metaboli-
cally) closely related to AdoHcy, in the urines of their 
CBS-deficient patients. 
The intracellular AdoMet/AdoHcy ratio, often 
termed the "methylation index," will determine 
the relative activities of most AdoMet-dependent 
methyltransferases (9). It can be inferred that this 
ratio may be relatively undisturbed in CBS-deficient 
patients by the fact that they seem not to suffer 
from the neurologic abnormalities associated with 
defective myelination that are common in patients 
with methylenetetrahydrofolate reductase (MTHFR) 
deficiency {lO) who, because of their low, or low 
normal, methionine and elevated tHcy concentra-
tions, may be expected have low AdoMet/ AdoHcy 
ratios. Jencks and Matthews stated that the physi-
ologic activity of MTHFR "must ... be determined 
by competition between AdoMet and AdoHcy for 
a common ligand-binding site and would therefore 
be expected to be very sensitive to the AdoMet/ 
AdoHcy ratio" (11). The inferred normality of this 
ratio in CBS-deficient patients would mean that there 
is no interference with the biosynthetic pathway to 
N l -methyltetrahydrofolate, and that there should be 
sufficient amounts of this compound to support me-
thylation of the abnormally elevated homocysteine. 
The increased input of methyl groups through 
homocysteine methylation raises the problem of 
how these methyl groups are to be disposed of. If 
utilization for homocysteine methylation keeps N l _ 
methyltetrahydrofolate at a low concentration, gly-
cine methyltransferase will be active and methyl 
groups will flow to sarcosine as a step in their 
ultimate oxidation. It would thus be of interest to 
assess quantitatively the rates of homocysteine 
methylation and sarcosine formation in CBS-deficient 
patients. 
The metabolic consequences of CBS deficiency 
might be expected to include abnormally low rates of 
synthesis of compounds distal to the enzyme block, 
including cystathionine and cysteine. Because a rela-
tively small residual activity of CBS may support a 
substantial flux of homocysteine into cystathionine 
(see below), the extent of the abnormalities in 
cystathionine and cysteine in a given patient will 
probably depend upon how much residual CBS activ-
ity is present. Cystathionine is present in normal 
human brain at high concentrations (12), but was 
present at most only in trace amounts in brains 
obtained at postmortem examination of three homo-
cystinuric individuals {l3,14). In the absence of data 
on the B6-responsiveness of these patients, it is uncer-
tain whether or not they had any residual CBS activ-
ity. Reliable assays of tissue cysteine concentrations 
have not been reported, but Mansoor et al. (6) found 
that in seven patients with homocystinuria and 
hypermethioninemia consistent with CBS deficiency 
(but not specified with respect to B6-responsiveness), 
plasma concentrations of total cyst(e)ine ranged from 
52 to 167~, below the mean normal value of ap-
proximately 250~ (6). 
The Mechanism of B6-responsiveness 
As discussed above, a major determinant of the clini-
cal prognosis for CBS-deficient patients is whether or 
not they are B6-responsive. In considering possible 
mechanisms of response it is important to realize that 
although B6 administration may bring about marked 
drops in plasma tHcy and methionine in responsive 
patients together with rises in abnormally low plasma 
cyst(e)ine concentrations, these patients are not re-
stored to biochemical normalcy. They usually con-
tinue to have some elevation of homocystine in 
plasma and urine, and respond abnormally to a me-
thionine load as judged by the extent and/or duration 
of elevations of plasma methionine and of plasma and 
urinary homocystine (15,16). 
In principle, the B6-induced response could be due 
either to stimulation of an alternative pathway for 
catabolism of methionine or homocysteine, or to 
stimulation of residual CBS activity. No evidence has 
been reported indicating stimulation of an alternative 
pathway, and indeed there is a possibility that the 
methionine transamination pathway, which is the 
major known alternative route for methionine degra-
dation, is inhibited in CBS-deficient patients (17). 
Furthermore, the genetic evidence now available 
proves that B6-responsiveness or nonresponsiveness is 
determined by some property of the mutant CBS 
itself. This was first indicated by the fact that B6-
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TABLE 11-1. Cystathionine ~-synthase activities in 
livers of cysathionine ~-synthase-deficient patients 
B6-responsive B6-nonresponsive 
B6 administration 
no yes no yes 
Liver CBS activity, % of mean control* Citation 
12.3** 
30.5** 0 
2.0 3.0 
1.2 4.6 
3.7 16.5 0 
9.4 11.7 0 
5.9 22.6 
5.6 24.7 
15.3** 55.1 
7.1 6.7 
6.2 10.7 
4.0 8.4 
* All in vitro assays with pyridoxal-5'-phosphate added. 
o 
o 
35 
36 
15 
37 
38 
** Patient with less marked homocystinuria: genetic status uncertain. 
responsiveness or nonresponsiveness is the same for all 
CBS-deficient sibs within a given sibship {4}, sug-
gesting that the same (or a closely linked) genetic 
mutation that makes an individual CBS-deficient de-
termines whether he will be B6-responsive. More 
recent studies of mutations in the CBS gene have 
firmly supported this conclusion. Striking examples 
include the findings that "the 'Celtic' mutation 
G307S appears to be incompatible with B6 respon-
siveness whether it is present in one or two copies in 
the patient" {I8}, and that the prevalent mutation 
I278T is associated in homozygotes with B6 respon-
siveness and, in compound heterozygotes, with some 
degree of B6 responsiveness {l9}' 
A few assays of CBS activity in livers of CBS-
deficient patients were performed before the discovery 
that this activity is expressed in normal cultured skin 
fibroblasts later obviated the need for studies of liver 
for diagnostic purposes. Those carried out with suffi-
cient sensitivity to detect relatively small residual 
CBS activities are summarized in table 11-1. Each B6-
responsive patient had detected residual activity, and 
treatment of the patient with therapeutic doses of B6 
almost invariably led to at least some increase in the 
hepatic activity. Pyridoxal 5'-phosphate was added in 
vitro for these assays. This fact, in addition to other 
available evidence {3}, makes it clear that in no in-
stance was the deficit in activity overcome merely 
by the addition of cofactor, as would be expected 
were these simply Km mutations. By contrast, no B6-
nonresponsive patient, whether or not given B6, had 
detected hepatic activity. * 
The physiologic importance of the relatively small 
activities of CBS in the B6-responsive patients has 
been indicated by measurements of the abilities of 
these patients to convert the sulfur of an oral load of 
methionine to inorganic sulfate, and by determina-
tion by nitrogen balance studies of their capacities to 
form cysteine from methionine. The normal human 
has the capacity to convert methionine sulfur to inor-
ganic sulfate at a rate of at least 84 millimole/day. In 
their basal states, B6-responsive CBS-deficient pa-
tients had a mean capacity of 8.3 millimole/day, and 
this capacity was increased by B6-treatment to 16.1 
millimole/day. Although each of these rates is small 
compared to normal, they are sizable compared to the 
normal methionine intake of some 8-12 millimole/ 
day {l5}. Finally, in contrast to normal humans, B6-
nonresponsive CBS-deficient patients do not maintain 
* The results of assays of CBS activities in cultured skin fibroblasts 
generally support the suggestion that B6-responsive patients have 
small residual activities of CBS, whereas B6-nonresponsive patients 
do not {33]. However, experience has shown that such results are 
fallible, at least in the sense that individuals who must have CBS 
activity in their liver may fail to manifest such activity in cultured 
fibroblasts. See, for example, de Franchis et at. {34}. 
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nitrogen balance when given methionine-adequate, 
cystine-free diets [20,21]. However, B6-responsive 
patients, even on normal B6 intakes, did remain in 
nitrogen balance on such diets. Titration of the 
amount of cystine required to maintain balance in 
a nonresponsive patient indicated that the B6-
responders must be synthesizing each day at least 
2.5-4.0 millimole of cysteine, a minimal value that is 
sizable compared to the normal methionine intake 
[21] and that, if stimulated by no more than two- to 
threefold, would become sufficient to metabolize such 
an intake. 
Are the Vascular-damaging Effects of 
Hyperhomocysteinemia Somehow Partially 
Mitigated in CBS-deficient Patients and in 
Heterozygotes for CBS Deficiency? 
The results of long-term treatment of CBS-deficient 
patients are now beginning to be reported [22-24]. 
B6-nontesponsive patients have been free of throm-
boembolic events, both those in Australia treated 
with betaine, B6, folate, and B12 [22,23], and those in 
Ireland given low-methionine diets (E Naughten, 
personal communication). This is surprising in view 
of the fact that, for the Australian patients, medica-
tions were given in doses that maintained plasma free 
homocyst(e)ine at "usually ... less that 60 J.1M" [22], 
so that plasma tHcy may have been at least twice this 
value [6]-i.e., at least 120J.1M. Compared with the 
levels of hyperhomocyst(e)inemia reported in the ab-
stracts and papers for this meeting to confer signifi-
cant relative risks of thromboembolic phenomena, 
120JlM is extremely high. Why have these patients 
been free of thromboembolism? 
The same question arises with regard to heterozy-
gotes for CBS deficiency. Such individuals are not 
overrepresented among individuals with premature 
vascular disease [25,26], and are at little, if any, 
increased relative risk for such disease [27,28]. Could 
it be that the vascular-damaging effects of hyper-
homocyst(e)inemia are somehow mitigated in indi-
viduals with partial or severe lack of CBS activiry? 
Perhaps methionine acts as a competitive structural 
inhibitor of this damage, and the elevated concentra-
tions of this amino acid in CBS-deficient individuals, 
in contrast to its normal or low concentrations in 
those with homocysteine methylation difficulties, is 
protective. Other differences exist between individu-
als with impaired CBS and impaired homocysteine 
methylation-the former have higher concentrations 
of AdoMet and lower concentrations of cystathionine 
and, perhaps, cysteine; and those with milder impair-
ments are likely to have hyperhomocyst(e)inemia only 
following intake of methionine (i.e., at times when 
the methionine concentration is also high), rather 
than fasting hyperhomocyst(e)inemia [29,30]. Again, 
if the transsulfuration pathway is normally not opera-
tive in endothelial cells and vascular tissues (a point 
upon which present evidence conflicts [31,32]), one 
might expect the pathophysiologic effects of a given 
extent of hyperhomocyst(e)inemia to be less severe 
with impairments of CBS than of homocysteine me-
thylation (JD Finkelstein, personal communication). 
These possible mitigating effects are not mutually 
exclusive. They may merit being borne in mind as 
work progresses on hyperhomocyst(e)inemia and its 
role in cardiovascular disease. Perhaps nature's experi-
ments with CBS-deficiency have lessons to teach us 
worthy of our attention. 
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